Journal ArticleOPEN ACCESS

Can drug price hikes via debranding be prevented?

  • Bokhari F
  • Lyons B
Prescriber (2017) 28(4) 44-46
DOI: 10.1002/psb.1563
N/ACitations
Citations of this article
8Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Steep price hikes following the debranding of off‐patent medicines are becoming increasingly common in the UK, adding hundreds of millions to the NHS drugs bill. But can anything be done to prevent this?

Cite

CITATION STYLE

APA

Bokhari, F., & Lyons, B. (2017). Can drug price hikes via debranding be prevented? Prescriber, 28(4), 44–46. https://doi.org/10.1002/psb.1563

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free